microdosing glp 1 for gut health GLP-1 is popular, but there's little evidence it works Microdosing Tirzepatide and Semaglutide for

The study received funding from Wellcome, Medical Research Council, European Union Horizon 2020 Programme, the National Institutes of Health (grants U01-DK105535, U01-DK085545 and UM-1DK126185), the National Institute for Health Research Oxford Biomedical Research Centre, the Canadian Institutes of Health Research, the Novo Nordisk Foundation, Boehringer Ingelheim and Diabetes Australia.

placebo for a 48-week period

Because type 2 diabetes and obesity are frequently co-occurring, this technique is very helpful in managing both conditions

These effects include the reduction of inflammation and oxidative stress, vasodilation, decreased arterial stiffness, and a reduction in myocardial fibrosiskey factors in the pathophysiology of HFpEF

References and Further Reading: Patel, S., & Niazi, S